losartan has been researched along with Debility in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is an oral antihypertensive agent that is rapidly metabolized to EXP3174 (angiotensin-subtype-1-receptor blocker) and EXP3179 (peroxisome proliferator-activated receptor gamma [PPARĪ³] agonist), which was shown in animal studies to reduce inflammation, enhance mitochondrial energetics, and improve muscle repair and physical performance." | 3.11 | Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults. ( Abadir, PM; Anders, NM; Bichara, MD; Buta, B; Carey, RM; de Cabo, R; Ferrucci, L; Gabrawy, MM; Khadeer, M; Kwak, MJ; Le, A; Lee, JL; Ma, L; Marx, R; Moaddel, R; Nidadavolu, L; Rudek, MA; Siragy, HM; Tian, J; Walston, JD; Westbrook, R; Wu, Y; Xue, QL; Yang, H; Yenokyan, G; Zhang, C, 2022) |
| "Losartan treatment for 4 weeks is associated with lower AT1R protein level, Nitrotyrosine, and Tau protein in the frontal cortex of aged IL-10-/- mice." | 1.72 | Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice. ( Abadir, PM; Cosarderelioglu, C; Saleh, N; Vajapey, R; Walston, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saleh, N | 1 |
| Cosarderelioglu, C | 1 |
| Vajapey, R | 1 |
| Walston, J | 1 |
| Abadir, PM | 2 |
| Lee, JL | 1 |
| Zhang, C | 1 |
| Westbrook, R | 1 |
| Gabrawy, MM | 1 |
| Nidadavolu, L | 1 |
| Yang, H | 1 |
| Marx, R | 1 |
| Wu, Y | 1 |
| Anders, NM | 1 |
| Ma, L | 1 |
| Bichara, MD | 1 |
| Kwak, MJ | 1 |
| Buta, B | 1 |
| Khadeer, M | 1 |
| Yenokyan, G | 1 |
| Tian, J | 1 |
| Xue, QL | 1 |
| Siragy, HM | 1 |
| Carey, RM | 1 |
| de Cabo, R | 1 |
| Ferrucci, L | 1 |
| Moaddel, R | 1 |
| Rudek, MA | 1 |
| Le, A | 1 |
| Walston, JD | 1 |
1 trial available for losartan and Debility
| Article | Year |
|---|---|
Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Frailty; Imidazoles; Losartan; P | 2022 |
1 other study available for losartan and Debility
| Article | Year |
|---|---|
Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Disease Models, Animal; Frailty; Inflammati | 2022 |